Crossref
The EMERALD-3 Trial: STRIDE with or without Lenvatinib plus TACE for Embolization-eligible Hepatocellular Carcinoma
Radiology: Imaging Cancer · 01.11.2026 · 8 (6)
DOI: 10.1148/rycan.269025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Radiology: Imaging Cancer, erschienen am 01.11.2026. Verfasst von Ridvan A Demirci und 1 weiteren Autor:innen. Die Arbeit nennt 1 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
ORCID-Profile: Ridvan A Demirci
Zitieren
APA
Demirci, R. A., & Andrade, G. H. (2026). The EMERALD-3 Trial: STRIDE with or without Lenvatinib plus TACE for Embolization-eligible Hepatocellular Carcinoma. Radiology: Imaging Cancer, 8(6). https://doi.org/10.1148/rycan.269025
Vancouver
Demirci RA, Andrade GH. The EMERALD-3 Trial: STRIDE with or without Lenvatinib plus TACE for Embolization-eligible Hepatocellular Carcinoma. Radiology: Imaging Cancer. 2026;8(6). doi:10.1148/rycan.269025
BibTeX
@article{Demirci2026,
author = {Demirci, Ridvan A and Andrade, Gustavo H},
title = {The EMERALD-3 Trial: STRIDE with or without Lenvatinib plus TACE for Embolization-eligible Hepatocellular Carcinoma},
journal = {Radiology: Imaging Cancer},
year = {2026},
volume = {8},
number = {6},
doi = {10.1148/rycan.269025}
}
EUVIMED